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Purpose: In womenwith postmenopausal osteoporosis, we investigated the effects of 24months of
treatment with alendronate (ALN) following 18 months of treatment with abaloparatide (ABL) or
placebo (PBO).
Methods: Women who completed ABL or PBO treatment in ACTIVE were eligible to receive up to
24months of ALN.We evaluated the incidence of vertebral and nonvertebral fractures and changes
in bone mineral density (BMD) during the entire 43-month period from ACTIVE baseline to the end
of ACTIVExtend and for the 24-month extension only.
Results: Five hundred fifty-eightwomen fromACTIVE’s ABL group and 581 from its PBO group (92%
of ABL and PBO completers) were enrolled. During the full 43-month treatment period, 0.9% of
evaluable women in the ABL/ALN group experienced a new radiographic vertebral fracture vs 5.6%
of women in the PBO/ALN group, an 84% relative risk reduction (RRR, P , 0.001). Kaplan–Meier
incidence rates for other reported fracture types were significantly lower for ABL/ALN vs PBO/ALN
(all P , 0.05). Gains in BMD achieved during ACTIVE were further increased during ACTIVExtend.
For ACTIVExtend only, RRR for vertebral fractures was 87% with ABL/ALN vs PBO/ALN (P = 0.001).
Adverse events were similar between groups. A supplemental analysis for regulatory authorities
found no hip fractures in the ABL/ALN group vs five in the PBO/ALN group.
Conclusions: Eighteen months of ABL followed by 24 months of ALN reduced the risk of vertebral,
nonvertebral, clinical, and major osteoporotic fractures and increased BMD. Sequential ABL fol-
lowed by ALN appears to be an effective treatment option for postmenopausal women at risk for
osteoporosis-related fractures. (J Clin Endocrinol Metab 103: 2949–2957, 2018)
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Anabolic drugs are important therapeutic agents forthe treatment of osteoporosis. To date, anabolic
drugs approved for the treatment of osteoporosis act via
PTH receptor type 1 (PTH1R). Although there are dif-
ferences between the agents, they also share common
characteristics. They stimulate bone formation and re-
sorption and have important effects on bone microstruc-
ture, mass, and strength, while transiently increasing the
remodeling space (1). Regulatory authorities limit the use of
anabolic drugs for postmenopausal osteoporosis to 18 to
24 months. An important characteristic typical of PTH and
PTH-related agents is loss of bone mass that occurs soon
after they are discontinued when an antiresorptive agent is
not subsequently administered (2). Whereas bone anabolic
agents increase the volume of bone, leading to an increase in
measured bone mineral density (BMD), antiresorptive
agents increase BMD mainly by decreasing the remodeling
space and increasing the degree of mineralization. For this
reason, sequential therapy with alendronate (ALN) fol-
lowing PTH 1–84 was employed in an extension of the
phase 2 trial, resulting in further gains in BMD (3). In-
vestigations of sequential and combination therapeutic
schemes employing PTH1R-mediated agents and anti-
resorptives have subsequently been performed (4–6). The
overall result has been that such studies, as well as recent
studies of romosozumab followed by an antiresorptive (7,
8), have demonstrated cumulative gains in BMD when a
drug that promotes bone formation is followed by an
antiresorptive. However, until now, an adequate, formal
fracture-endpoint trial of sequential therapywith a PTH1R-
mediated anabolic agent followed by a potent anti-
resorptive agent has not been reported. As a result, the
prescribing information for such agents has not addressed
measures to sustain their beneficial effects.
Abaloparatide (ABL) is a PTH-related peptide analog
that increased BMD and reduced fracture risk in post-
menopausal women with osteoporosis (9). Fracture risk
reduction with ABL at vertebral and nonvertebral sites
was rapid and robust. Furthermore, ABL had advanta-
geous effects on BMD in comparison with teriparatide.
Based on prior experience with agents employing related
mechanisms of action, continuation of therapy with an
antiresorptive agent was considered necessary to sustain
the effects of ABL. Hence, ACTIVExtendwas undertaken
to formally assess the longer-term safety and efficacy of
extended treatment with ALN following 18 months of
ABL or placebo (PBO). The initial results during the first
6 months of ALN in the extension study were previously
reported (10). The final results provide new information
about the clinical effect of antiresorptive treatment in
participants who had been treated with ABL in com-
parison with those who had been treated with PBO.
Methods
ACTIVE description
Inclusion criteria for ACTIVE have been described in detail by
Miller et al. (9). ACTIVE enrolled 2463 postmenopausal women
with osteoporosis, aged 49 to 86 years. Women#65 years of age
who had radiographic evidence of vertebral fracture at any time or
who had a nonvertebral fracture within 5 years were eligible when
they also had a BMD T-score of less than 22.5 but greater
than25.0 at the lumbar spine (LS) or femoral neck (FN).Women
who were .65 years of age who met these fracture criteria were
allowed to enroll when their LS or FN BMD T-score was less
than 22.0 but greater than 25.0. Women older than 65 years
could also enroll when their LS or FN BMD T-score was less
than23.0 but greater than25.0, evenwhen they did not meet the
fracture criteria. ACTIVE participants were randomized in a 1:1:1
fashion to receive 18months of treatment with either blinded daily
subcutaneous injections of ABL (80 mg) or matching PBO or daily
open-label subcutaneous injections of teriparatide (20 mg).
As described by Cosman et al. (10), following completion of
ACTIVE, there was an interval of ;1 month during which
eligible participants were recruited, gave informed consent, and
were enrolled into ACTIVExtend. Thus, there was an off-
treatment period of up to 40 days, followed by 24 months on
ALN, for a total of 43 months included in the integrated
ACTIVE–ACTIVExtend study period [Fig. 1(a)].
ACTIVExtend inclusion and exclusion criteria
Women who completed visit 9, the end-of-treatment visit for
ACTIVE, and who had been randomized to either blinded ABL
or blinded PBO were eligible for enrollment into ACTIVExtend
when they were appropriate candidates for treatment with
ALN, were .80% compliant with study medication during
ACTIVE, when not.40 days had passed since their visit 9, and
when they had signed a new written informed consent for the
extension study. Women were excluded from ACTIVExtend
when they had a treatment-related serious adverse event (AE)
during ACTIVE, had stopped taking study medication, were
noncompliant, or had withdrawn from ACTIVE.
Efficacy and safety were analyzed according to the ACTIVE
treatment group assignment (either ABL or PBO); hereafter, the
ACTIVExtend treatment groups are designated ABL/ALN and
PBO/ALN. Study personnel and participants remained blinded
to initial treatment assignment (ABL or PBO) while participants
were receiving open-label ALN (70 mg) weekly during the first
6 months of therapy.
The study was conducted in accordance with the ethical
principles contained in the Declaration of Helsinki and in
compliance with Good Clinical Practice guidelines and all other
applicable local regulatory and ethical requirements.
Primary efficacy endpoint
Efficacy and safety endpoints for the first 6 months of
ACTIVExtend have been described in detail (10). The primary
efficacy endpoint of the integrated ACTIVE–ACTIVExtend
study was the proportion of participants with one or more
incidents of new vertebral fracture as determined by the method
of Genant et al. (11) comparing the ACTIVE baseline spine
x-rays with the spine x-rays at the end of ACTIVExtend (i.e., at
cumulative month 43). The population evaluable for the pri-
mary efficacy endpoint was designated as the modified intent-
to-treat (mITT) population.
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Additional efficacy endpoints
Additional efficacy endpoints for the integrated ACTIVE–
ACTIVExtend study included time to first incident nonvertebral,
clinical, and major osteoporotic fracture from ACTIVE baseline
through cumulative months 25, 31, 37, and 43; mean percentage
change fromACTIVE baseline at months 25,
31, 37, and 43 in BMD at LS, total hip (TH),
and FN; andmedian percentage change from
ACTIVE baseline at months 25, 31, 37, and
43 in serum procollagen type I N-terminal
propeptide (s-PINP) and serum carboxyl-
terminal cross-linking telopeptides of
type I collagen (s-CTX).
Prespecified exploratory efficacy
endpoints in ACTIVExtend using
ACTIVExtend baseline
Prespecified exploratory efficacy analyses
using the ACTIVExtend baseline (cumulative
month 19, the beginning of treatment with
ALN) included incidence of new vertebral
fracture at months 6 and 24 of ACTIVExtend.
Times to first incidents of nonvertebral frac-
ture, clinical fracture, and major osteoporotic
fracturewere analyzedwith the Kaplan–Meier
method. Mean absolute changes from
ACTIVExtend baseline in BMD at LS, TH,
and FN and median percentage changes
from ACTIVExtend baseline in s-PINP and
s-CTX were analyzed at ACTIVExtend
months 6, 12, 18, and 24.
Safety endpoints
Safety findings reported in the present
study are for the 24 months of monotherapy
with ALN administered to all participants
in ACTIVExtend. These include AEs, vital
signs, ECGs, clinical laboratory evaluations
(including hematology, serum chemistry, and
urinalysis), and ABL antibody assessments.
Participants were withdrawn from the study
when they had a confirmed .7% decrease
from baseline of ACTIVExtend in BMD,
treatment-related serious AEs, refusal of
treatment, the inability to complete the study
procedures, or when they were lost to follow-
up. Treatment-emergent AEs were coded
using theMedical Dictionary for Regulatory
Activities, version 17.1.
Study visits
The ACTIVE follow-up visit, visit 10,
;1 month after participants’ visit 9, corre-
sponded to day1ofACTIVExtend.Vital signs,
ECG, clinical laboratory measurements, and
bone turnover markers were assessed on day 1
of ACTIVExtend as baseline values for the
24-month ALN treatment period. A total
of six clinic visits were scheduled during
ACTIVExtend at day 1 and months 3 (cu-
mulative month 22), 6 (cumulative month
25), 12 (cumulative month 31), 18 (cumulative month 37), and
24 (cumulative month 43).
In ACTIVExtend, each participant was assigned to receive
24 months of open-label ALN (70 mg) orally once per week. In
addition toALN, all participants also received supplemental calcium
Figure 1. Study design and participant enrollment and disposition. (a) Study design.
Participants were treated with ABL, teriparatide, or PBO for 18 mo in ACTIVE. Participants
who received ABL or PBO during ACTIVE were eligible for enrollment in ACTIVExtend. A gap
in treatment of up to 1 mo (from mo 18 to 19) was allowed for rollover and reconsenting
from ACTIVE to ACTIVExtend. Former ABL and former PBO participants began monotherapy
with ALN at cumulative mo 19 for up to 24 mo. (b) Participant enrollment and disposition.
*As reported by Cosman et al. (10). †Baseline for the integrated 43-mo analysis was day 1 of
ACTIVE. ‡Baseline of the ACTIVExtend analysis was day 1 of ACTIVExtend (cumulative mo
19). §As reported by Miller et al. (9). ¶A modified intent-to-treat (mITT) population, including
those participants with an evaluable postbaseline spine radiograph assessment, was
evaluated for incident new vertebral fractures. Fourteen ABL/ALN participants (one because
she was not included in the mITT population for ACTIVE and 13 because they did not have
a postbaseline spinal radiograph) were not included in the ACTIVExtend mITT, yielding an
ABL/ALN mITT of n = 544; 13 PBO/ALN participants (two because they were not included in
the ACTIVE mITT and 11 for no postbaseline spinal radiograph) were excluded from the
mITT, yielding an mITT n = 568. BL, baseline.
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(500 to 1000 mg) and vitamin D (400 to 800 IU) at dosages de-
termined by the investigator. Participants were instructed to take
their first dose of ALN within 1 week of their day 1 visit. At
ACTIVExtend study month 6, 12, 18, and 24 visits, safety labo-
ratory tests were performed, participants underwent dual-energy
x-ray absorptiometry of the hip and spine formeasurement of BMD,
and fasting blood samples were drawn for bone turnover markers.
At the ACTIVExtendmonth 6 visit, spinal x-rayswere performed to
diagnose incident vertebral fractures, whereas nonvertebral fractures
were determined clinically and confirmed by radiographic reports
and/or radiographs. At each visit, participants had a diary review
and were questioned about use of concomitant medications and
occurrence of AEs. At month 24 of ACTIVExtend, participants had
clinical and radiologic fracture assessments, and any AE or clinical
laboratory abnormality that was recorded at the month 24 visit was
subsequently monitored until it resolved or had become chronic
or stable.
Statistical analysis
For the integrated ACTIVE–ACTIVExtend analyses, the
results from the final assessment made before or at the initiation
of study drug in ACTIVE were used as baseline. For the ex-
ploratory ACTIVExtend 24-month efficacy analyses and the
ACTIVExtend safety analyses, baseline measurements are de-
fined as those collected at ACTIVExtend baseline (cumulative
month 19, beginning of treatment with ALN).
Fisher’s exact test was used to evaluate between-treatment dif-
ferences in the incidence of new vertebral fracture, and the log-rank
test, the Kaplan–Meier method, and the proportional hazardmodel
were used to assess time to first incident nonvertebral, clinical, and
major osteoporotic fracture. The analysis of covariance model with
missing data imputation by last observation carried forward was
used for BMD at each anatomic site. The mixed-effect repeated
measure model was used to assess log ratio of postbaseline over
baseline value for bone turnover maker levels. Also reported in this
study is an additional analysis of fracture endpoints requested by
regulatory authorities to evaluate both the ACTIVExtend intent-to-
treat (ITT) population and the full ACTIVE ITT population, in-
cluding participants who did not continue into ACTIVExtend.
Results
Of the 1243 women who completed the ABL or PBO arm of
ACTIVE, 1139 (92%) were enrolled in ACTIVExtend be-
ginning 20 November 2012. The mean (SD) duration be-
tween the last dose of ABL or PBO and the first dose of ALN
was 33.8 (8.04) days for ABL/ALN and 33.6 (8.02) days for
PBO/ALN treatment groups. A total of 1005 participants
completed the 24-month treatment period with ALN mon-
otherapy [Fig. 1(b)]. Participants from the former ABL and
former PBO groups who entered ACTIVExtend were well
matched for demographic and baseline characteristics and
were representative of the ACTIVE population in whole.
The characteristics of those patients at ACTIVE baseline
and at ACTIVExtend baseline are presented in Table 1. At
Table 1. Demographics and Baseline Characteristics of the ACTIVExtend Population at Baseline of ACTIVE
and at the Baseline of ACTIVExtend (Cumulative Mo 19)
At ACTIVE Baseline At ACTIVExtend Baseline
Characteristic PBO/ALN (n = 581) ABL/ALN (n = 558) PBO/ALN (n = 581) ABL/ALN (n = 558)
Age
Mean, y (SD) 68.5 (6.3) 68.6 (6.5) 70.1 (6.29) 70.2 (6.54)
,65, n (%) 114 (19.6) 106 (19.0) 86 (14.8) 93 (16.7)
65 to , 75, n (%) 370 (63.7) 351 (62.9) 359 (61.8) 327 (58.6)
$75, n (%) 97 (16.7) 101 (18.1) 136 (23.4) 138 (24.7)
Race/ethnicity, n (%)
White 447 (76.9) 433 (77.6) 447 (76.9) 433 (77.6)
Asian 106 (18.2) 101 (18.1) 106 (18.2) 101 (18.1)
Black or African American 18 (3.1) 19 (3.4) 18 (3.1) 19 (3.4)
Other 10 (1.7) 5 (0.9) 10 (1.7) 5 (0.9)
Hispanic or Latino 139 (23.9) 124 (22.2) 139 (23.9) 124 (22.2)
Mean years since menopause (SD) 19.8 (7.9) 20.4 (8.2) 21.3 (7.94) 21.9 (8.23)
Region, n (%)
North America 7 (1.2) 9 (1.6) 7 (1.2) 9 (1.6)
South America 157 (27.0) 145 (26.0) 157 (27.0) 145 (26.0)
Europe 312 (53.7) 305 (54.7) 312 (53.7) 305 (54.7)
Asia 105 (18.1) 99 (17.7) 105 (18.1) 99 (17.7)
Mean body mass index, kg/m2 (SD) 25.0 (3.50) 24.9 (3.49) 25.0 (3.62) 24.9 (3.67)
Prevalent vertebral fracture at baseline, n (%) 132 (22.8)a 123 (22.0) 140 (24.1) 124 (22.3)
At least one priorb nonvertebral fracture, n (%) 282 (48.5) 272 (48.7) 293 (50.4) 277 (49.6)
Mean BMD T-score (SD)
LS 22.91 (0.82) 22.88 (0.86) 22.87 (0.867) 22.11 (0.997)
TH 21.91 (0.76) 21.88 (0.72) 21.93 (0.758) 21.63 (0.742)
FN 22.17 (0.68) 22.15 (0.62) 22.20 (0.695) 21.95 (0.656)
Some data in this table originally appeared in Cosman et al. (10).
aOf 580 participants.
bBased on fractures that occurred prior to ACTIVE baseline visit, excluding those of spine, breast bone, knee cap, toes, fingers, skull, and facial bones.
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ACTIVExtend baseline, mean BMD levels and the propor-
tion of participants with vertebral and nonvertebral fractures
differed between the two groups, consistent with the prior
treatment of ABL vs PBO.
At the end of the full 43-month treatment period of the
integrated ACTIVE–ACTIVExtend study, the 86% rel-
ative risk reduction (RRR) of new vertebral fractures that
had been demonstrated during 18 months of treatment in
ACTIVE was effectively sustained. After 18 months of
treatment with ABL followed by 24 months of ALN,
0.9% (n = 5) of evaluable women in the ABL/ALN group
experienced a new radiographic vertebral fracture, whereas
after 18 months of PBO followed by 24 months of
treatment with ALN, 5.6% (n = 32) of evaluable women
in the PBO/ALN group experienced a new radiographic
vertebral fracture, representing an RRR of 84% (P ,
0.001; Fig. 2).
Kaplan–Meier incidence rates for nonvertebral,
clinical, and major osteoporotic fractures for the in-
tegrated ACTIVE–ACTIVExtend analysis are summa-
rized in Supplemental Table 1. Incidence rates for all
three fracture types were significantly lower in the ABL/
ALN group compared with the PBO/ALN group. The
separation from PBO observed at month 18 of ACTIVE
was sustained at cumulative month 43 (month 24 of
ACTIVExtend) for all three fracture types (Fig. 3), with
significant risk reductions in the ABL/ALN group of
39%, 34%, and 50% compared with the PBO/ALN
group for nonvertebral, clinical, and major osteopo-
rotic fractures, respectively (all P , 0.05). Supple-
mental Table 1 also displays the ACTIVE ITT plus
ACTIVExtend ITT analysis, which included participants
treated in ACTIVE who did not subsequently enroll in
ACTIVExtend. Five participants in the PBO group and
no participants in the ABL group had an incident hip
fracture during the full 43 months in this combined
population (P = 0.027).
Percentage changes from baseline in BMD at the LS,
TH, and FN for the integrated ACTIVE–ACTIVExtend
analysis are shown in Fig. 4. At each anatomic site, gains
in BMD realized during ACTIVE with ABL treatment
relative to PBO were sustained during 24 months of
monotherapy with ALN.
The bone turnover markers s-PINP and s-CTX were
evaluated in a subset of participants from each treatment
group as shown in Fig. 4. During treatment with ABL in
ACTIVE, s-PINP increased to a peak median value of
;79% greater than baseline values at month 1 before
decreasing to ;30% above baseline values at month 18.
During treatment with PBO in ACTIVE, s-PINP decreased
from baseline, reaching a nadir of 19% below baseline
values atmonth 3 of ACTIVE. Among participants treated
with ABL in ACTIVE, s-CTX increased to a peak of
;15% greater than baseline at month 3 before decreasing
to baseline levels by month 18. Partic-
ipants in the PBO group in ACTIVE
had decreases from baseline in s-CTX,
reaching a nadir of 24% lower than
baseline values at month 6 of ACTIVE.
At month 19, by which time partici-
pants had been off ABL-SC and PBO for
;30 days, s-PINP and s-CTX levels
were approaching ACTIVE baseline
levels. As expected, during treatment
with ALN (months 19 to 43), levels of
both s-PINP and s-CTX decreased
well below ACTIVE baseline levels by
month 25 and remained suppressed
through month 43 in both the ABL/
ALN and PBO/ALN treatment groups.
Prespecified exploratory analyses
of endpoints from ACTIVExtend
baseline to end of study
As described previously, a prespecified
exploratory analysis of the 24 months of
ALN treatment (from ACTIVExtend
baseline to the end of the 24-month
treatmentperiodwithALNmonotherapy,
corresponding with cumulative months
Figure 2. Incidence of new vertebral fractures in ACTIVE, ACTIVExtend only, and ACTIVE
plus ACTIVExtend. mITT populations, representing those participants who had baseline and
also postbaseline spinal x-rays at the specified time points, were evaluated for vertebral
fracture rates. In ACTIVE, treatment with ABL was associated with an 86% RRR for new
vertebral fractures compared with PBO. A gap in treatment of up to 1 mo (from mo 18 to
19) was allowed for rollover and reconsenting from ACTIVE to ACTIVExtend. During the
ACTIVExtend period only (mo 19 to 43), prior treatment with ABL was associated with an
RRR of 87% compared with prior treatment with PBO. For the full ACTIVE/ACTIVExtend
study period (mo 0 to 43), treatment with ABL was associated with an 84% RRR compared
with PBO. *P # 0.001 for ABL vs PBO and for ABL/ALN vs PBO/ALN. ACTIVE findings were
reported by Miller et al. (9).
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19 to 43) was performed for fracture
endpoints. For radiographically deter-
mined vertebral compression fractures,
from ACTIVExtend baseline to end of
study, there was an RRR of 87% (P =
0.001; Fig. 2) in the ABL/ALN group [n =
2 (0.37%)] compared with the PBO/ALN
group [n = 16 (2.82%)]. Analysis of
the incidences of nonvertebral, clinical,
andmajor osteoporotic fractures for the
24-month ACTIVExtend treatment
period demonstrated fewer fractures in
the ABL/ALN group for all three frac-
ture types, but these differences were
not statistically significant compared
with the PBO/ALN group: 15 non-
vertebral fractures in ABL/ALN vs 20 in
PBO/ALN [hazard ratio (HR), 0.76; P =
0.422]; 23 clinical fractures in ABL/
ALN vs 24 in PBO/ALN (HR, 0.98;
P = 0.941); 12 major osteoporotic
fractures in ABL/ALN vs 17 in PBO/
ALN (HR, 0.72; P = 0.374; Supple-
mental Table 1).
During the 24-month ACTIVExtend
period, BMD increased at the LS, TH,
and FN sites for both groups, as
shown in Fig. 4. However, the mag-
nitude of the differences between
groups did not increase, but rather
decreased slightly: at the start of the
extension, BMDs in the former ABL
group were significantly higher than
in the former PBO group, as previ-
ously reported (9). Therefore, per-
centage changes from the beginning of
the extension cannot be compared, and
absolute BMD changes are reported.
During the 24-month ACTIVExtend pe-
riod, BMD increased from ACTIVExtend
baseline for both groups, but the
between-groups differences were small.
Mean (SD) absolute increases in
BMD from ACTIVExtend baseline to
ACTIVExtend month 24 at the LS
were 0.0265 (0.0451) and 0.0479
(0.0378) for the ABL/ALN and PBO/
ALN groups, respectively (P, 0.001).
For the TH, the respective gains were
0.0166 (0.0249) and 0.0210 (0.0205)
(P = 0.001), and for the FN, the
gains were 0.0114 (0.0285) and
0.0143 (0.0264) (P = 0.073). Median
Figure 3. Time-to-event analyses of nonvertebral fractures, clinical fractures, and major
osteoporotic fractures from ACTIVE baseline at mo 43. Curves indicate time to the first
event. (a) Nonvertebral fractures were defined as fractures excluding those of the spine,
sternum, patella, toes, fingers, skull, and face and those with high trauma. (b) Clinical
fractures were defined as all fractures that would cause a patient to seek medical care,
regardless of the level of trauma, including clinical spine. (c) Major osteoporotic fractures
were defined as fractures of the wrist, upper arm, hip, and clinical spine. A gap in treatment
of up to 1 mo (from mo 18 to 19) was allowed for rollover and reconsenting from ACTIVE
to ACTIVExtend. Risk reduction = (1 2 HR) 3 100. Data for mo 0 to 18 originally appeared
in Miller et al. (9).
2954 Bone et al ACTIVExtend in Postmenopausal Osteoporosis J Clin Endocrinol Metab, August 2018, 103(8):2949–2957
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/103/8/2949/5001732 by Leiden U
niversity / LU
M
C
 user on 15 August 2019
percentage changes in s-PINP at the end of ACTIVExtend
were similar in both groups (ABL/ALN,258.4%; PBO/ALN,
259.2%; P = 0.387), as were median percentage changes in
s-CTX(ABL/ALN,264.6%;PBO/ALN,264.9%;P=0.152).
Safety and AEs
The overall incidence of AEs, including severe and
serious AEs, during the ALN treatment period was
similar for both study groups (Table 2) and was con-
sistent with the recognized profile of ALN. The most
common treatment-emergent AEs (TEAEs) were arthral-
gia, upper respiratory infection, and back pain. The in-
cidence of serious TEAEs was 11.8% in the ABL/ALN
group and 10.0% in the PBO/ALN group; 5.4% of the
ABL/ALN group and 6.2% of the PBO/ALN group had at
least one TEAE that led to study drug discontinuation. No
cases of atypical femoral fracture or osteonecrosis of the
jaw were reported.
Discussion
The results of ACTIVE and the completed ACTIVExtend
trial in postmenopausal women at high risk for fracture
demonstrate the effectiveness of a treatment sequence
comprised of initial anabolic treatment with ABL for
18 months, followed by continuation of treatment with
ALN for up to 2 additional years. The results include
favorable effects on fracture risk across anatomic sites
Figure 4. Percentage changes from ACTIVE baseline to end of ACTIVExtend in BMD and in bone turnover markers. (a–c) Mean percentage
changes from baseline in BMD at: (a) LS, (b) TH, and (c) FN. Error bars represent 95% CIs. (d and e) Median percentage changes in s-PINP (d)
and in s-CTX (e). Error bars represent interquartile ranges. A gap in treatment of up to 1 mo (from mo 18 to 19) was allowed for rollover and
reconsenting from ACTIVE to ACTIVExtend. Former PBO and former ABL participants began monotherapy with ALN at mo 19. *P , 0.001 for
ABL vs PBO and for ABL/ALN vs PBO/ALN; †P , 0.05 for ABL/ALN vs PBO/ALN. Data for mo 0 to 18 originally appeared in Miller et al. (9), and
data for mo 25 originally appeared in Cosman et al. (10).
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and consistent, progressive gains in BMD at the TH, FN,
and LS. Although the study was not designed to assess
hip fracture risk, an ACTIVE ITT plus ACTIVExtend
ITT analysis requested by regulatory authorities dem-
onstrated no hip fractures in the ABL/ALN group vs five
in the PBO/ALN arm.
Because the effects of anabolic agents on bone mass
are generally reversible if the treatment is discontinued,
extension therapy should be considered as a component
of any treatment plan with an anabolic agent. Rittmaster
et al. (3) demonstrated that ALN following PTH 1–84
resulted in not only preservation but also a further
increase in BMD. This point has been reinforced by
subsequent clinical trials (5, 8, 12), and the approach
has recently been reviewed by Cosman et al. (13).
However, such a treatment sequence has not been tested
until now in a fracture-endpoint trial employing a
PTH1R-mediated anabolic agent. The efficacy of ABL
demonstrated in ACTIVE followed by 24 months of ALN
in ACTIVExtend provides evidence to support the use of
sequential therapy with 18 months of ABL followed by
ALN. This information should be of use to clinicians.
During the extension, both groups received ALN, but
the former ABL group had an RRR for new vertebral
fractures during the extension of 87%, virtually identical
to the large RRR with ABL vs PBO in ACTIVE. This
relative reduction in the risk of fracture is all the more
impressive in comparison with an active control of
known efficacy. It suggests that advantageous effects of
ABL on bone strength were maintained on ALN treat-
ment, whereas they were not achieved on ALN alone.
Bone resorption, as indicated by s-CTX, increased tran-
siently but was back to baseline by the end of ACTIVE.
Thus, we did not see an extra increase in BMD on ALN
as we might have expected if the bone resorption rate
were still high at the transition. In fact, the increases in
BMD on ALN differed little between groups, with a
slightly greater gain in the former PBO groups at some
anatomic sites. Furthermore, the RRR for nonvertebral,
clinical, major osteoporotic, and hip fractures tended
toward a more favorable effect of the ABL/ALN se-
quence. Thus, there appears to be a cumulative benefit
that favors the ABL/ALN sequence of treatment over
ALN monotherapy introduced at the time of the tran-
sition from ABL to ALN.
A sequential treatment strategy using ABL followed by
ALN is attractive for several reasons: ABL produces a
prompt and consistent reduction in fracture risk, associ-
ated with increased BMD at vertebral and hip sites (9),
further increasing bone mass by reducing the remodeling
space and increasing mineralization. Although anabolic
therapies are generally administered for #2 years, ALN
can be administered for a substantially longer period,
with a sustained effect on BMD lasting several years be-
yond the end of active treatment (14). Thus, an ABL/ALN
sequence can provide a rapid and substantial initial benefit
as well as a sustained favorable effect, employing a rela-
tively inexpensive medication in the continuation phase.
This study has limitations with respect to its size and
duration. It was not powered to demonstrate a significant
reduction in nonvertebral fractures during the extension
period; studies of greater size and duration would be
needed to confirm the favorable trend observed. The only
antiresorptive agent evaluated was ALN, but that drug
has been extensively evaluated during many years, and it
is a widely used antiresorptive agent internationally.
Whereas our results are specific to the agents tested,
future studies may address the use of other agents or
longer term treatment and the use of a similar strategy in
other populations.
Conclusion
Eighteen months of treatment with ABL followed by
24 months of treatment with ALN reduced the risk of
vertebral, nonvertebral, clinical, and major osteoporotic
Table 2. Treatment-Emergent AEs in ACTIVExtend, Cumulative Mo 19 to 43
Summary of TEAEs, ACTIVExtend Safety
Population (N = 1133) PBO/ALN (n = 580), n (%) ABL/ALN (n = 553), n (%)
$1 TEAE 466 (80.3) 452 (81.7)
$1 Severe TEAE 40 (6.9) 38 (6.9)
$1 Serious TEAE 58 (10.0) 65 (11.8)
$1 TEAE leading to death 2 (0.3) 0
$1 TEAE leading to discontinuation 36 (6.2) 30 (5.4)
Most frequently ($5% in either group) reported TEAEs
Arthralgia 58 (10.0) 54 (9.8)
Upper respiratory tract infection 51 (8.8) 40 (7.2)
Back pain 34 (5.9) 36 (6.5)
Hypertension 33 (5.7) 27 (4.9)
Pain in extremity 31 (5.3) 23 (4.2)
Osteoarthritis 21 (3.6) 28 (5.1)
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fractures and produced large increments in BMD of the
LS, TH, and FN. These findings demonstrate that the
sequence of ABL followed by ALN can be a highly ef-
ficacious treatment option for postmenopausal women
who are at risk for osteoporosis-related fractures.
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